从上市主体资格来看，古参堂已满足 "合法存续满 3 年、主营业务稳定、管理层无重大变动" 等基础合规要求。后续只需根据目标上市板块，达成对应的财 务指标即可推进上市进程，例如 A 股要求净利润累计超 3000 万元，港股 18A 板块则可豁免盈利要求。 可持续发展能力同样是古参堂冲击上市的重要底气。品牌已搭建起独立的生产、采购、销售全链条体系，拥有清晰的盈利逻辑，技术转化效率与产品复购率 均表现良好。同时，品牌业务布局多元，有效杜绝了过度依赖政策或单一产品的经营风险。 值得一提的是，古参堂掌握的酶转化法技术，还推动了人参产业的整体升级。在稀有人参皂苷领域，具备高纯度、多组分特质，且持有 NCI 药典收录、临 床试验批文等合规资质的企业，往往因技术稀缺性更易通过上市审核。古参堂凭借技术与资质的双重优势，在资本化进程中将更具竞争力。 厚植根基，蓄力上市：天乐园古参堂资本化发展的核心优势 在核心竞争力层面，古参堂已构筑起难以复制的技术壁垒。其持有的酶转化法制备人参稀有皂苷技术，曾斩获国家技术发明奖，不仅具备领先的技术优势， 更实现了成熟的产业化落地，为品牌的市场竞争力提供了硬核支撑。 在资本化发展的道路上，古参堂已 ...

Group 1 - The health industry is becoming a core pillar for high-quality economic and social development, with functional foods and skincare products being key sectors to meet public demand for a better life and establish a comprehensive health service system [1] - The Beijing University Life Sciences East China Industry Research Institute's Functional Food/Skin Care Engineering Technology Center will hold its inauguration ceremony on January 18, 2026, in Qidong, Jiangsu [1] - The center aims to promote the development of the life sciences industry, facilitate the transformation of scientific achievements, and provide public technical services as a new high-end platform [3] Group 2 - The center has made significant technological achievements in plant synthetic biology and natural product innovation, particularly in the transformation and industrialization of rare ginsenosides from ginseng and Panax notoginseng, achieving world-leading levels [3] - The center will continue to promote the application of its projects in functional foods and skincare products, addressing the slow metabolism and absorption issues of traditional ginseng saponins [3] - With the global aging population and increasing attention to public health, the functional food and skincare market is expected to experience significant growth, with a focus on natural products as essential components [10]

Group 1 - The company, Gucantang, has met the core compliance requirements for the listing process, including legal existence for over 3 years, stable main business operations, and no significant changes in core management [1] - Financially, Gucantang can adapt to different listing board requirements, such as the A-share market's cumulative net profit requirement of over 30 million yuan, or the exemption of profit-related requirements for the Hong Kong 18A board, providing multiple listing pathways [1] - Gucantang has established a strong patent protection barrier in the technology sector, with its self-developed enzyme conversion technology winning a national invention award, indicating mature industrial application capabilities and a differentiated competitive advantage [1] Group 2 - The company has built a complete and independent production, procurement, and sales system, demonstrating a clear and traceable profit logic, with indicators like improved technology conversion efficiency and stable product repurchase rates reflecting a healthy operational trend [3] - Gucantang's technological breakthroughs in producing rare ginsenosides, such as Rh2, inject new momentum into the industry and enhance its suitability for listing [3] - In the rare ginsenoside sector, companies with high purity and multi-component output capabilities, along with compliance qualifications, are more likely to meet listing review requirements, and Gucantang's accumulation in this field adds significant weight to its listing process [3]

Industry Overview - Synthetic biology has gained significant attention from both the scientific and investment communities, with increasing research and application prospects across various fields [1][2] - The global synthetic biology market was approximately $12.2 billion in 2022, showing a year-on-year growth of 28.42%, and is projected to reach $15.1 billion in 2023 and $19 billion in 2024, with a forecast of $24.3 billion by 2025 [1] - Major countries, including the US, UK, EU, and China, are intensifying their strategic investments and policy support in synthetic biology, positioning it as a strategic high ground in future global competition [1][3] Company Developments - Haizheng Pharmaceutical has established a joint venture, Lian Sheng Synthetic, with a registered capital of 350 million yuan, aiming to enter the synthetic biology sector [2] - Shenghe Biotechnology has launched China's first production line for natural product biosynthesis, which will serve various industries including cosmetics and pharmaceuticals [2] - Lian Sheng Synthetic is set to invest 170 million yuan in a flexible production line for synthetic biology, with its first product expected to be launched in August [5] Market Dynamics - The economic value of synthetic biology and bio-manufacturing is projected to reach $100 billion by 2025, with an expectation that 60% of material production will be achieved through bio-manufacturing methods [5] - The industry is characterized by a competitive landscape where companies are striving to convert midstream technologies into marketable products, emphasizing the importance of industrialization capabilities [5][9] Challenges and Opportunities - The transition from laboratory to commercial application in synthetic biology faces multiple challenges, including technical feasibility, engineering conversion, and market adaptability [7][8] - The industry is experiencing a "valley of death" in industrialization, where many promising technologies fail to scale up due to the lack of pilot testing [8] - Despite the challenges, the integration of AI and machine learning is expected to enhance research capabilities and support the development of synthetic biology [6] Strategic Insights - The current landscape indicates a need for innovation to avoid price competition and to develop high-value products that can lead the market [9] - The establishment of supportive policies at the provincial and national levels in China is anticipated to further guide and promote the healthy development of the synthetic biology industry [6]

Core Viewpoint - Synthetic biology is rapidly transforming various aspects of life, including healthcare, energy, and food production, driven by interdisciplinary research and innovation in biological engineering [1][3]. Group 1: Industry Development - The field of synthetic biology and biomanufacturing aims to design and modify biological systems to address challenges in materials, food, energy, environment, and health [1]. - In 2022, the National Development and Reform Commission emphasized the promotion of synthetic biology technology innovation in the "14th Five-Year Plan for Bioeconomic Development" [3]. - The establishment of the Synthetic Biology and Biomanufacturing Institute at Tianjin University aims to respond to the challenges of the biotechnology revolution and train innovative talents in this field [5]. Group 2: Research and Innovations - Researcher Sun Yuanxia has developed a sugar bioconversion synthesis platform, achieving a breakthrough in the precise total synthesis of rare sugars from carbon dioxide, significantly reducing resource dependency and production time from years to hours [2]. - Tianjin University's research team has utilized synthetic biology strategies to produce rare ginsenosides, known for their high bioactivity and health benefits, providing a new approach for efficient production [5]. - The advancements in biological engineering are expected to lower production costs and enhance accessibility to beneficial compounds like rare ginsenosides for the general public [5].